ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Consensus Rating of “Buy” from Analysts

ABIVAX Société Anonyme (NASDAQ:ABVX) has been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $38.67.

ABVX has been the subject of several research analyst reports. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities began coverage on ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They set an “outperform” rating and a $33.00 price target on the stock.

ABIVAX Société Anonyme Price Performance

Shares of NASDAQ:ABVX opened at $8.81 on Wednesday. ABIVAX Société Anonyme has a one year low of $8.06 and a one year high of $17.02. The firm has a 50 day simple moving average of $9.73 and a 200 day simple moving average of $11.51.

Hedge Funds Weigh In On ABIVAX Société Anonyme

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its position in ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. Walleye Capital LLC increased its position in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares during the period. abrdn plc raised its stake in ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after buying an additional 198,225 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares during the period. 47.91% of the stock is currently owned by institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.